In 2025, new data indicates a significant decline in venture capital funding for biotech companies compared to 2024, despite an increase in mergers and acquisitions (M&A) activities. The analysis, published by The Business Journals, highlights how the biotech sector is currently experiencing financial challenges. Although there is an uptick in M&A deals, which typically signals market confidence, the reduced venture capital investments reflect potential investor caution within the biotech industry. This funding lag suggests that venture capitalists are possibly re-evaluating risks amidst evolving market dynamics. For biotech start-ups seeking funds, navigating the landscape has become increasingly competitive. Industry experts suggest that biotechs may need to demonstrate more robust business models or novel innovations to attract venture capital. Overall, the article underscores the current paradox in the biotech industry: while M&A activity grows, venture capital support seems to be faltering.
The Business JournalsNew data shows 90% of buyers unable to afford new Brisbane apartments
April 29, 2026
In Brisbane, a startling new statistic reveals that nine out of ten potential buyers are priced out of the city’s new apartment market. With soaring